Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Molecular Origami: Start-Ups Tackle Protein Folding

This article was originally published in Start Up

Executive Summary

Start-ups are developing novel therapeutics that work by shepherding faulty proteins into their normal conformations. The risky approach, if successful, could dramatically increase the pharmaceutical arsenal. Drug companies remain skeptical, prefering to wait for clinical validation of the existing compounds before inking big deals.
Advertisement

Related Content

Start-Up Eidos Surfs Crest Of TTR Amyloidosis Wave
Preventing Toxic Effects Of Protein Aggregation In Parkinson’s Disease
Where Are They Now? Checking In With Four Alzheimer’s Disease Start-Ups
Deals Of The Week: Pfizer/FoldRx, Takeda/Orexigen, Bayer/Kythera ...
Deals Of The Week: Pfizer/FoldRx, Takeda/Orexigen, Bayer/Kythera ...
Pfizer Adds To Specialty Care Division With Purchase Of FoldRx
Pfizer Adds To Specialty Care Division With Purchase Of FoldRx
Best of the Blog: START-UP ( August 2008)
Best Laid Plans: Pfizer's Torcetrapib Tanks
Merck Nabs Pole Position in RNAi With $1.1 Billion Sirna Buy

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091205

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel